Epclusa is a prescription antiviral medication used to treat chronic hepatitis C virus (HCV) infection. It is the first treatment approved to work against all six major genotypes of hepatitis C, which means most patients can be treated without needing extensive genetic testing of their virus beforehand. The FDA approved it for both adults and children aged 3 and older.
How Epclusa Treats Hepatitis C
Epclusa is a combination tablet containing two antiviral drugs that attack the hepatitis C virus from different angles. One component blocks the virus’s ability to copy its genetic material, acting like a faulty building block that gets inserted into the viral RNA and stops the copying process cold. The other disables a viral protein essential for the virus to replicate and assemble new copies of itself. Together, they shut down the virus’s life cycle at two critical points, making it extremely difficult for hepatitis C to survive or develop resistance.
This dual-target approach is what makes Epclusa effective across all six genotypes of hepatitis C. Older treatments often worked well against one or two genotypes but poorly against others, requiring doctors to identify the exact viral strain before choosing a drug. Epclusa simplified that process considerably.
Who Is Eligible for Treatment
Epclusa is approved for adults and children aged 3 and older with chronic hepatitis C, regardless of genotype. It covers a broad range of patients: those with no liver damage, those with compensated cirrhosis (where the liver is scarred but still functioning), and those with decompensated cirrhosis (where the liver is severely damaged and struggling to work). Patients with decompensated cirrhosis take Epclusa in combination with an additional antiviral called ribavirin.
Current guidelines from the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America recommend treating all people with chronic hepatitis C. For treatment-naive adults, Epclusa taken once daily for 12 weeks is one of two equally recommended first-line options under a simplified treatment approach. This simplified pathway applies to patients with any HCV genotype who have either no cirrhosis or compensated cirrhosis. One exception: patients with compensated cirrhosis and genotype 3 need additional resistance testing before starting, since genotype 3 can be slightly harder to clear.
Cure Rates Across Genotypes
Hepatitis C treatment success is measured by something called SVR12, which means the virus is undetectable in the blood 12 weeks after finishing treatment. This is considered a cure. A large meta-analysis pooling data from 1,277 patients found that Epclusa achieved an SVR12 rate of 94.2%. In clinical practice, cure rates for most genotypes are even higher, often exceeding 95% for genotypes 1, 2, 4, 5, and 6.
Genotype 3 has historically been the most stubborn to treat. For patients with genotype 3 and decompensated cirrhosis, adding ribavirin to the regimen significantly improved cure rates. For genotypes 1 and 2, ribavirin did not provide a meaningful boost, so it is only added when the clinical situation calls for it.
What Treatment Looks Like
For most patients, treatment is straightforward. You take one tablet once a day, with or without food, for 12 weeks. There are no injections. The standard adult tablet contains 400 mg of sofosbuvir and 100 mg of velpatasvir.
Children aged 3 and older are dosed by weight. Kids under about 37 pounds take a lower-dose version available as oral pellets. Those between roughly 37 and 66 pounds get an intermediate dose, and children weighing 66 pounds or more take the same dose as adults.
Patients with decompensated cirrhosis follow a slightly different path. If they can tolerate ribavirin, they take it alongside Epclusa for 12 weeks. If ribavirin is not an option, the Epclusa-only course extends to 24 weeks. For patients who have already tried and failed a previous hepatitis C treatment, the combination with ribavirin typically runs for 24 weeks.
Common Side Effects
In clinical trials of patients without cirrhosis or with compensated cirrhosis, the most frequently reported side effects were headache (22% of participants), fatigue (15%), nausea (9%), weakness (5%), and insomnia (5%). Most of these were mild to moderate.
Side effects are more common when ribavirin is added. In the decompensated cirrhosis trials where patients took Epclusa plus ribavirin, fatigue occurred in 32% of participants and anemia in 26%. Nausea (15%), headache (11%), insomnia (11%), and diarrhea (10%) were also frequently reported. The anemia is a known effect of ribavirin rather than Epclusa itself, and it typically resolves after treatment ends.
Hepatitis B Reactivation Risk
Epclusa carries an FDA boxed warning, the most serious type of safety alert, about the risk of hepatitis B reactivation. In patients who carry both hepatitis C and hepatitis B, treating the hepatitis C can cause the hepatitis B virus to flare up, sometimes with severe consequences including liver failure and death. This has occurred even in patients whose hepatitis B appeared to have resolved in the past.
Because of this risk, all patients are tested for current or prior hepatitis B infection before starting Epclusa. Those who test positive are monitored closely during and after treatment, and may need hepatitis B antiviral therapy running alongside their hepatitis C treatment.
Interactions With Acid-Reducing Medications
If you take a proton pump inhibitor (PPI) for acid reflux or heartburn, this is worth paying attention to. Acid-reducing medications can interfere with how well your body absorbs Epclusa, potentially making it less effective. The general guidance is to avoid PPIs during treatment if possible. When there is no alternative, you should take Epclusa with food and take the PPI at least 4 hours afterward, never at the same time. Maximum allowed doses during treatment are lower than usual: for example, omeprazole (Prilosec) is capped at 20 mg once daily, and lansoprazole (Prevacid) at 15 mg once daily.
Your prescriber will review all your current medications before you start treatment, since other drug interactions exist beyond acid reducers. Bringing a complete medication list, including over-the-counter drugs and supplements, helps avoid problems that could reduce the treatment’s effectiveness.